Peer-reviewed veterinary case report
RNA disruption test shows CHOP chemo works in dog lymphoma
By Parissenti, Amadeo M et al.·Published in BMC veterinary research·2019·Laurentian University, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: RNA disruption indicates CHOP therapy efficacy in canine lymphoma.
- Species:
- dog
Plain-English summary
A 9-year-old Golden Retriever diagnosed with lymphoma was treated with a chemotherapy protocol called CHOP, which includes several medications. During treatment, the vet monitored the dog's response by taking samples to measure RNA disruption, which can indicate how well the cancer is responding to therapy. The results showed that higher RNA disruption scores were linked to better outcomes, meaning the dog had a longer period without the cancer worsening. This information can help vets adjust treatment plans more effectively if needed.
People also search for: dog lymphoma treatment · Golden Retriever cancer prognosis · CHOP chemotherapy for dogs
Abstract
BACKGROUND: Assessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms. RESULTS: An increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival. CONCLUSIONS: Predicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31842875/